由于失败的血栓预防,与静脉血栓栓塞性疾病相关的因素
Santiago Grillo Pérez1,2, Paula Ruiz-Talero3,4, Oscar Mauricio Muñoz Velandia3,4
1Internal Medicine Department, Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia. sgrillo@javeriana.edu.co.
Thrombosis journal
|December 7, 2023
概括
医学患者的失败血栓预防与更高的BMI,活跃癌症,白细胞病和重症监护室 (ICU) 停留有关. 这些因素可能需要调整治疗策略以获得更好的结果.
科学领域:
- 医学研究 医学研究
- 临床药理学 临床药理学
- 预防血栓形成的预防方法
背景情况:
- 有限的证据存在于与住院医疗患者失败的血栓预防相关的因素.
- 了解这些因素对于优化预防策略至关重要.
研究的目的:
- 在住院医疗患者中,独立地确定与失败的血栓预防治疗 (FT) 相关的临床因素.
- 评估特定患者特征与FT发展之间的关联.
主要方法:
- 一个嵌入在历史队列中的病例控制研究.
- 涉及单变量和多变量回归分析,以确定与FT相关的因素.
- 将FT发病的患者 (病例) 与没有FT发病的患者 (对照组) 进行比较.
主要成果:
- 更高的身体质量指数 (BMI),活跃的癌症,白细胞病和重症监护室 (ICU) 的要求独立地与FT相关.
- 患有FT的患者的BMI中位数较高 (26.3 vs. 25 kg/m2),需要ICU治疗的比例更高 (48% vs. 24.8%).
- 肺栓塞是FT组中最常见的栓塞事件 (53.4%).
结论:
- 高BMI,活跃的癌症,白细胞症和ICU需求是与失败的血栓预防治疗相关的重要因素.
- 这些发现表明,需要探索为高风险患者调整的血栓预防方案.
- 需要进一步的研究来确定基于这些已识别的因素修改血栓预防的临床益处.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
Disorders of Hemostasis
926
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
926
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Return
4.7K
The circulatory system plays a crucial role in ensuring the optimal functioning of the human body. One of its critical components is venous return - the process that completes the blood circulation cycle. This article will delve into the concept of venous return, how it works, and its significance to our health.
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
4.7K
Extrinsic and Intrinsic Pathways of Hemostasis
7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K
Clot Retraction and Fibrinolysis
6.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.2K


